These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 24237190)

  • 1. Chromium supplementation for menstrual cycle-related mood symptoms.
    Brownley KA; Girdler SS; Stout AL; McLeod MN
    J Diet Suppl; 2013 Dec; 10(4):345-56. PubMed ID: 24237190
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Luteal phase treatment of premenstrual dysphoric disorder improves symptoms that continue into the postmenstrual phase.
    Yonkers KA; Pearlstein T; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):317-21. PubMed ID: 15780701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Duloxetine treatment for women with premenstrual dysphoric disorder: a single-blind trial.
    Ramos MG; Hara C; Rocha FL
    Int J Neuropsychopharmacol; 2009 Sep; 12(8):1081-8. PubMed ID: 19250561
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of mood changes throughout the reproductive cycle in healthy women without premenstrual dysphoric disorders.
    Gonda X; Telek T; Juhász G; Lazary J; Vargha A; Bagdy G
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Dec; 32(8):1782-8. PubMed ID: 18721843
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychosocial functioning in women with premenstrual dysphoric disorder before and after treatment with sertraline or placebo.
    Pearlstein TB; Halbreich U; Batzar ED; Brown CS; Endicott J; Frank E; Freeman EW; Harrison WM; Haskett RF; Stout AL; Yonkers KA
    J Clin Psychiatry; 2000 Feb; 61(2):101-9. PubMed ID: 10732657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of a unique oral contraceptive (Yasmin) in the management of premenstrual dysphoric disorder.
    Freeman EW
    Eur J Contracept Reprod Health Care; 2002 Dec; 7 Suppl 3():27-34; discussion 42-3. PubMed ID: 12659404
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chromium potentiation of antidepressant pharmacotherapy for dysthymic disorder in 5 patients.
    McLeod MN; Gaynes BN; Golden RN
    J Clin Psychiatry; 1999 Apr; 60(4):237-40. PubMed ID: 10221284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variable dosing of sertraline for premenstrual exacerbation of depression: a pilot study.
    Miller MN; Newell CL; Miller BE; Frizzell PG; Kayser RA; Ferslew KE
    J Womens Health (Larchmt); 2008; 17(6):993-7. PubMed ID: 18681820
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study.
    Jermain DM; Preece CK; Sykes RL; Kuehl TJ; Sulak PJ
    Arch Fam Med; 1999; 8(4):328-32. PubMed ID: 10418540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of intermittent, luteal phase sertraline treatment of premenstrual dysphoric disorder.
    Halbreich U; Bergeron R; Yonkers KA; Freeman E; Stout AL; Cohen L
    Obstet Gynecol; 2002 Dec; 100(6):1219-29. PubMed ID: 12468166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment pattern of symptom expression in premenstrual dysphoric disorder.
    Pearlstein T; Yonkers KA; Fayyad R; Gillespie JA
    J Affect Disord; 2005 Apr; 85(3):275-82. PubMed ID: 15780697
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pyridoxine (vitamin B6) and the premenstrual syndrome: a randomized crossover trial.
    Doll H; Brown S; Thurston A; Vessey M
    J R Coll Gen Pract; 1989 Sep; 39(326):364-8. PubMed ID: 2558186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sertraline in the treatment of premenstrual dysphoric disorder.
    Yonkers KA; Halbreich U; Freeman E; Brown C; Pearlstein T
    Psychopharmacol Bull; 1996; 32(1):41-6. PubMed ID: 8927673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gonadotropin-releasing hormone agonist in the treatment of premenstrual symptoms with and without ongoing dysphoria: a controlled study.
    Freeman EW; Sondheimer SJ; Rickels K
    Psychopharmacol Bull; 1997; 33(2):303-9. PubMed ID: 9230648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predictors of response to sertraline treatment of severe premenstrual syndromes.
    Freeman EW; Sondheimer SJ; Polansky M; Garcia-Espagna B
    J Clin Psychiatry; 2000 Aug; 61(8):579-84. PubMed ID: 10982201
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study.
    Wang M; Hammarbäck S; Lindhe BA; Bäckström T
    Acta Obstet Gynecol Scand; 1995 Nov; 74(10):803-8. PubMed ID: 8533564
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gender differences in clinical presentation and response to sertraline treatment of generalized anxiety disorder.
    Steiner M; Allgulander C; Ravindran A; Kosar H; Burt T; Austin C
    Hum Psychopharmacol; 2005 Jan; 20(1):3-13. PubMed ID: 15551351
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mood and performance changes in women with premenstrual dysphoric disorder: acute effects of alprazolam.
    Evans SM; Haney M; Levin FR; Foltin RW; Fischman MW
    Neuropsychopharmacology; 1998 Dec; 19(6):499-516. PubMed ID: 9803426
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder.
    Pearlstein TB; Stone AB; Lund SA; Scheft H; Zlotnick C; Brown WA
    J Clin Psychopharmacol; 1997 Aug; 17(4):261-6. PubMed ID: 9241004
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.